Scarica l'app Stockscreener
49.42
0.82%
0.5655
Uniqure Nv Borsa (QURE) Ultime notizie
Enterprise value to EBIT forward of uniQure N.V. – LSX:A1XDTV - TradingView
Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsight - PR Newswire UK
UniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program Advances - Yahoo Finance
Mizuho raises uniQure stock price target to $68 on FDA meeting optimism - Investing.com
uniQure Prices Upsized $225 Million Public Offering to Advance Gene Therapy Pipeline - Minichart
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $68 - Moomoo
uniQure Prices $45.50 Stock Offering; Underwriting With Leerink Partners Nets $242.7 Million - TradingView
uniQure (NASDAQ: QURE) prices $225M underwritten share offering - Stock Titan
uniQure (NASDAQ: QURE) raises $211.5M net to fund AMT-130 launch plans - Stock Titan
uniQure (NASDAQ: QURE) files Rule 144 resale notice listing recent insider sales - Stock Titan
UniQure (QURE) Gains Regulatory Support from FDA Under New Leade - GuruFocus
5 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey
uniQure N.V. (QURE) Prices $225M Public Offering of Shares - GuruFocus
What’s next in line for FDA reversals (RGNX:NASDAQ) - Seeking Alpha
uniQure N.V. (QURE) Stock Dips Following $225M Share Offering Announcement - Blockonomi
uniQure prices upsized $225M public offering of ordinary shares - MSN
UniQure Prices $225 Million Ordinary Stock Offering - Moomoo
QURE Raises Offering Size to $225M, Priced Below Previous Close - GuruFocus
uniQure (QURE) Shares Climb 7.6% with Notable Price Increase - GuruFocus
uniQure locks in $225M from a new share sale - Stock Titan
uniQure prices $225M public offering at $45.50 per share By Investing.com - Investing.com South Africa
uniQure prices $225M public offering at $45.50 per share - Investing.com
uniQure Announces Pricing of $225 Million Public Offering of Ordinary Shares - Quiver Quantitative
uniQure Announces Pricing of Upsized $225 Million Public Offering - GlobeNewswire
Gene Therapy AMT-260 Shows Early Seizure Reductions in Refractory Mesial Temporal Lobe Epilepsy, Phase 1 Cohort Data Show - NeurologyLive
QURE Stock Soars As FDA Backs Accelerated Huntington’s Therapy Path - timothysykes.com
Barclays Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $65 - 富途牛牛
QURE Stock Roars As FDA Clears Faster Path For AMT-130 - StocksToTrade
uniQure initiates $150 million public offering - The Pharma Letter
symbol__ Stock Quote Price and Forecast - CNN
uniQure commences $150 million public offering of shares - Investing.com UK
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy - Sahm
uniQure (QURE) Launches $150M Public Offering Amid After-Hours D - GuruFocus
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
UniQure surges on plans to seek US nod for gene therapy - MSN
QURE: New Offering Managed by Leerink Partners and Stifel - GuruFocus
UniQure's experimental drug shows early promise in difficult-to-treat epilepsy - MSN
uniQure (NASDAQ: QURE) seeks $150M in equity and pre-funded warrants ahead of AMT-130 BLA - Stock Titan
uniQure commences $150 million public offering of shares By Investing.com - Investing.com South Africa
UniQure Announces Planned $150 Million Public Offering - marketscreener.com
uniQure starts $150M share sale, with $22.5M extra option - Stock Titan
UniQure Announces $150 Million Proposed Public Offering - 富途牛牛
uniQure (QURE) Secures FDA Reversal for Huntington's Disease Gen - GuruFocus
Form 8K uniQure N.V. For: 22 June By Investing.com - Investing.com India
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene TherapyRegenxbio (NASDAQ:RGNX) - Benzinga
Uniqure N.v. Insider Sold Shares Worth $9,371,612, According to a Recent SEC Filing - marketscreener.com
uniQure Reports Promising Preliminary Results for AMT-260 Gene Therapy in Refractory Mesial Temporal Lobe Epilepsy Phase I/IIa Trial 1 – Minichart - Minichart
uniQure (QURE) CEO sells 206,100 shares and exercises stock options - Stock Titan
Uniqure N.v. Insider Sold Shares Worth $526,485, According to a Recent SEC Filing - Moomoo
uniQure (QURE) director exercises 11,685 options, sells shares under 10b5-1 - Stock Titan
uniQure (QURE) director Jack Kaye sells shares after exercising stock options - Stock Titan
uniQure Announces Promising Early Data for AMT-260 - TipRanks
uniQure reports preliminary AMT-260 Phase I/IIa low-dose results; 3 of 6 patients show 79–100% seizure reduction - TradingView
uniQure (QURE) shows mixed but promising early AMT-260 MTLE results - Stock Titan
0.03%
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):